ONCONOVA THERAPEUTICS INC (ONTX)

Traws Pharma Announces New Employee Inducement Grants

Traws Pharma Announces New Employee Inducement Grants

NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards...

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

Translational science to characterize pathways impacted by rigosertib may help to guide future clinical studies and combination treatment regimen for difficult-to-treat cancers

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024...

Onconova stock falls 10% on preclinical data for lymphoma drug (NASDAQ:ONTX)

Onconova (ONTX) stock fell 10% after the biotech company presented preclinical data for its drug candidate narazaciblib in the treatment of mantle cell lymphoma. Read more here.

Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s...

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

Onconova presenting at NobleCon19 Dec 4-5 in Boca Raton, FL...

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023

Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft...

Onconova Expands Leadership Team with Two Key Appointments

Onconova Expands Leadership Team with Two Key Appointments

Onconova Expands Leadership Team: Victor Moyo named Chief Medical Officer, Meena Arora joins as Vice President Global Medical Affairs and R&D ...

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023Additional studies support broad potential, especially in cyclin-dependent cancers ...

Encouraging Rigosertib Data Presented at EADV as Late Breaker

Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage...

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results

Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023

Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023